Bevacizumab,Durvalumab,Olaparib,Carboplatin,Paclitaxel
AstraZeneca,roche,Merck
['avastin', 'imfinzi', 'ovarian', 'brca', 'lynparza']
patients with newly diagnosed ovarian cancer without a brca1/2 mutation treated first with chemotherapy plus avastin and imfinzi then with maintenance avastin plus imfinzi and lynparza had improved progression-free survival. #asco23 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.